NOVEL TRICYCLIC HETEROCYCLIC CARBALDEHYDE COMPOUND AND PHARMACEUTICAL COMPOSITION, CONTAINING SAME, FOR IRE1α INHIBITION

Title:

NOVEL TRICYCLIC HETEROCYCLIC CARBALDEHYDE COMPOUND AND PHARMACEUTICAL COMPOSITION, CONTAINING SAME, FOR IRE1α INHIBITION

Document Type and Number:

WIPO Patent Application WO/2024/072110

Kind Code:

A1

Abstract:

The present invention relates to a novel tricyclic heterocyclic carbaldehyde compound and a pharmaceutical composition, containing same, for IRE1α inhibition and, more specifically, to a novel tricyclic heterocyclic carbaldehyde compound and a pharmaceutical composition, containing same, for treatment or prevention of IRE1α-related diseases.

More Like This:

WO/2005/010063	VINYL MONOMER, POLYMER DERIVED FROM SUCH MONOMER, AND A LIGHT-EMITTING DEVICE USING SUCH POLYMER
JP2013103941	INHIBITOR OF E1 ACTIVATING ENZYME
JP5795755	Inhibitor of renal medulla external potassium channel

Inventors:

KIM JI SOOK (KR)
JUNG SEUNG HYUN (KR)
KIM MIN JEONG (KR)
PARK WON GI (KR)
CHOI JAE YUL (KR)
AHN YOUNG GIL (KR)

Application Number:

PCT/KR2023/015052

Publication Date:

April 04, 2024

Filing Date:

September 27, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

HANMI PHARMACEUTICAL CO LTD (KR)

International Classes:

C07D493/04; A61K31/4025; A61K31/453; A61K31/496; A61K31/5377; A61P35/00

Attorney, Agent or Firm:

Y.P.LEE, MOCK & PARTNERS (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: NOVEL CO-CRYSTAL OF ENAVOGLIFLOZIN

Next Patent: DIGITAL REAL-TIME PCR ANALYSIS METHOD